Clene Inc. (NASDAQ:CLNNW) Sees Large Increase in Short Interest

Clene Inc. (NASDAQ:CLNNW) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 7,100 shares, a growth of 42.0% from the September 30th total of 5,000 shares. Based on an average daily volume of 7,000 shares, the days-to-cover ratio is presently 1.0 days.

Clene Stock Down 34.8 %

Shares of CLNNW traded down $0.02 during trading hours on Tuesday, reaching $0.03. 7,600 shares of the company traded hands, compared to its average volume of 10,807. The stock has a fifty day simple moving average of $0.04 and a 200 day simple moving average of $0.04. Clene has a fifty-two week low of $0.02 and a fifty-two week high of $0.09.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.